The Gynecologic Cancer Steering Committee (GCSC) was established in 2006. In its monthly meetings, the GCSC addresses the design, prioritization, and evaluation of concepts for phase 2, 2/3, and 3 clinical trials in adult gynecologic cancers. The GCSC also recognizes its role in fostering collaboration between groups and institutions engaged in conducting trials in gynecologic cancers. View the GCSC member roster as of November 7, 2025. The committee may periodically hold clinical trials planning meetings (CTPMs) to focus on specific clinical trial related topics.
Task Forces
- The Gynecologic Cancer Task Force (GCTF) was established to discuss clinical trial concepts in the different disease subtypes. View the GCTF member roster as of February 12, 2026.
Committee Highlights
The following are highlights from recent committee and task force activities:
- Refining the Approach to Endometrial Cancer in the Immunotherapy Era
In January 2024, the GCSC convened a CTPM to propose clinical trials to optimize treatment under new immune checkpoint inhibitor treatment paradigms. Read the executive summary and publication in JNCI. - Defining and Targeting Molecular Pathways to Direct Personalized Value-added Treatments for Patients with Epithelial Ovarian Cancer
In February 2021, the GCSC convened a CTPM to identify and prioritize novel and existing therapeutics and combinations targeting ovarian cancer subgroups in an effort to advance precision therapy of epithelial ovarian cancer. Read the executive summary and publication on biomarkers for ovarian cancer in JCO Precision Oncology. - Moving Forward in Cervical Cancer - Enhancing Susceptibility to DNA Repair Inhibition and Damage
The GCSC convened a CTPM in October 2018 to review the biologic understanding of HPV-related cervical cancer and its susceptibility to DNA damage repair modulation to maximize new therapeutic strategies for the treatment of advanced or metastatic cervical cancer. Read the executive summary and publication in JNCI. - Designing Targeted Trials for Targeted Endometrial Cancer Populations Using Targeted Agents
The GCSC convened a CTPM in January 2016 with the goal of integration of molecular and/or histologic stratification into endometrial cancer management. Read the executive summary, and publications in Oncotarget and Gynecologic Oncology.
Contact
For more information, contact NCI CCCT Program Director, Mehrdad Mohseni, M.D. at mehrdad.mohseni@nih.gov